A phase 3 trial of semagacestat for treatment of Alzheimer's disease.

By R. Doody, R. Raman, M. Farlow, T. Iwatsubo, Bruno Vellas, S. Joffe, K. Kieburtz, F. He, Xiaoying Sun, Ronald G. Thomas and 4 more. New England Journal of Medicine, 2013

1,067 citations recorded by the source corpus.

Subfields: Molecular Biology, Physiology, Psychiatry and Mental health

View Paper: https://www.semanticscholar.org/paper/0d1dacaf883abefe9a6a1d4bc70acb69843486e3

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

1. D. Selkoe
2. John Hardy
3. David Watson
4. Sokratis G. Papageorgiou
5. K. Yiannopoulou

In Physiology

1. John Hardy
2. D. Selkoe
3. D. Holtzman
4. David Watson
5. L. Mucke
6. G. Bu
7. P. Reddy
8. Christopher M. Dobson

In Psychiatry and Mental health

1. John Hardy
2. D. Selkoe

Citations in the corpus

• Reconsideration of Amyloid Hypothesis and Tau Hypothesis in Alzheimer's Disease (2018, background): “Notably, the symptoms of AD worsened in a clinical trial of γ-secretase inhibitor (Doody et al., 2013).”
• Alzheimer Disease: An Update on Pathobiology and Treatment Strategies (2019, neutral): “However, the trial was halted early due to concerns of worsening cognition, increased incidence of skin cancers and infection, and weight loss relative to placebo (Doody et al., 2013).”
• The amyloid hypothesis of Alzheimer's disease at 25 years (2016, background): “The only such compound to reach Phase 3 testing was semagacestat, but the trial was terminated after ~12 months of dosing due to adverse events (Doody et al, 2013).”